Overexpression of Wilms Tumor 1 Gene as a Negative Prognostic Indicator in Acute Myeloid Leukemia

Chromosomal aberrations are useful in assessing treatment options and clinical outcomes of acute myeloid leukemia (AML) patients. However, 40∼50% of the AML patients showed no chromosomal abnormalities, i.e., with normal cytogenetics aka the CN-AML patients. Testing of molecular aberrations such as FLT3 or NPM1 can help to define clinical outcomes in the CN-AML patients but with various successes. Goal of this study was to test the possibility of Wilms’ tumor 1 (WT1) gene overexpression as an additional molecular biomarker. A total of 103 CN-AML patients, among which 28% had overexpressed WT1, were studied over a period of 38 months. Patient’s response to induction chemotherapy as measured by the complete remission (CR) rate, disease-free survival (DFS) and overall survival (OS) were measured. Our data suggested that WT1 overexpression correlated negatively with the CR rate, DFS and OS. Consistent with previous reports, CN-AML patients can be divided into three different risk subgroups based on the status of known molecular abnormalities, i.e., the favorable (NPM1mt/no FLT3ITD), the unfavorable (FLT3ITD) and the intermediate risk subgroups. The WT1 overexpression significantly reduced the CR, DFS and OS in both the favorable and unfavorable groups. As the results, patients with normal WT1 gene expression in the favorable risk group showed the best clinical outcomes and all survived with complete remission and disease-free survival over the 37 month study period; in contrast, patients with WT1 overexpression in the unfavorable risk group displayed the worst clinical outcomes. WT1 overexpression by itself is an independent and negative indicator for predicting CR rate, DFS and OS of the CN-AML patients; moreover, it increases the statistical power of predicting the same clinical outcomes when it is combined with the NPM1 mt or the FLT3 ITD genotypes that are the good or poor prognostic markers of CN-AML.

• Publication year

  2014

• Venue

  PLoS ONE

• Publication date

  2014-03-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1371/journal.pone.0092470PMID 24667279PMCID 3965428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Personalized Approach to Diagnosis and Treatment of Acute Myeloid

  2013influential reference
• Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

  2013cited by this paper
• Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

  2011cited by this paper
• WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia

  2011cited by this paper
• Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

  2011cited by this paper
• miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level

  2011cited by this paper
• Wilms’ tumor protein and FLT3‐internal tandem duplication expression in patients with de novo acute myeloid leukemia

  2011cited by this paper
• Midkine: A Novel Prognostic Biomarker for Cancer

  2010cited by this paper
• Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia

  2010cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity

  2009cited by this paper
• Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

  2007cited by this paper
• A tumor suppressor and oncogene: the WT1 story

  2007cited by this paper
• A tumor suppressor and oncogene: the WT1 story

  2007cited by this paper
• Regulation of insulin-like growth factor I receptor gene expression by the wilms’ tumor supressor WT1

  2007cited by this paper
• HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells

  2005cited by this paper
• Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.

  2004cited by this paper
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

  2004cited by this paper
• Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia

  2003cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Wilms tumor gene expression in acute myeloid leukemias.

  1997influential reference
• Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1).

  1996cited by this paper

• Wilms’ Tumor 1 Gene Expression as a Predictive Marker for Clinical Outcome of Acute Myeloid Leukemia in Iraqi Population: A Prospective Study

  2024influential citation
• Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia

  2023cites this paper
• Screening and In Silico Functional Analysis of MiRNAs Associated with Acute Myeloid Leukemia Relapse.

  2022cites this paper
• Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation

  2021cites this paper
• Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia

  2021cites this paper
• The Prognostic Impact of WT1 Expression Levels, Mutations, and SNP rs16754 in AML Patients: A Retrospective Cohort Study

  2021cites this paper
• WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia.

  2020cites this paper
• One-Step duplex droplet digital PCR for WT1 overexpression.

  2020cites this paper
• Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics

  2020cites this paper
• High expression of DOCK2 indicates good prognosis in acute myeloid leukemia

  2019cites this paper
• Dynamic changes in the level of WT1 as an MRD marker to predict the therapeutic outcome of patients with AML with and without allogeneic stem cell transplantation.

  2019cites this paper
• Monitoring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia Using WT1 Expression Level in Relation to Immunopheno Typing

  2019cites this paper
• 多核苷酸多态性分析在异基因造血干细胞移植后嵌合状态检测中的应用

  2019cites this paper
• Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation

  2019cites this paper
• Heterogeneity of human WT1 gene.

  2017cites this paper
• Recent advances in diagnostic and prognostic aspects of acute myeloid leukaemia.

  2017cites this paper
• High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions

  2017influential citation
• Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia

  2017cites this paper
• Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR

  2017cites this paper
• Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation

  2016cites this paper
• WT1 Gene Overexpression in Oncohematological Disorders: Theoretical and Clinical Aspects (Literature Review)

  2016cites this paper
• Wilms tumor (WT)1 gene expression in children with acute leukemia in Serbia

  2016cites this paper
• [Expression of WT1 gene in children with acute myeloid leukemia].

  2016cites this paper
• High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia

  2016influential citation
• Molecular landscape in acute myeloid leukemia: where do we stand in 2016

  2016cites this paper
• WT1 Mutation in Childhood Cancer.

  2016cites this paper
• High expression of Inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia

  2015cites this paper
• Analysis of the expression of PHTF1 and related genes in acute lymphoblastic leukemia

  2015cites this paper
• A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells

  2015cites this paper
• Molecular Genetic Markers in Acute Myeloid Leukemia

  2015cites this paper
• Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis

  2015cites this paper
• The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia.

  2015cites this paper
• 急性T淋巴细胞白血病异基因造血干细胞移植后WT1基因表达及其与预后关系

  2015cites this paper
• Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia

  2015influential citation
• Prognostic implications of expression of the Wilms tumor 1 (WT1) gene in acute leukemia (experience from South Egypt).

  2015cites this paper
• Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population.

  2015cites this paper
• Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia

  2015influential citation